Christopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.
Christopher Pleyer, MD
Advertisement
Articles by Christopher Pleyer, MD
Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Advertisement
Latest Updated Articles
Dr. Pleyer on Remaining Questions With Ibrutinib Plus Short-Course Fludarabine in CLLPublished: October 8th 2020 | Updated:
Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLLPublished: October 8th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5